Skip to main content

Table 3 Post-diagnostic exposure to aspirin and odds of all-cause mortality cancer-specific death in breast cancer patients

From: Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink

Post-diagnostic aspirin exposure All cause deaths n (%) Controls n (%) Unadjusted OR (95% CI) P AdjustedaOR (95% CI) P Additionally adjustedbfor stage and grade OR (95% CI) P
No. prescriptions low dose       
  0 1,653 (73.2) 5,153 (76.5) 1.00   1.00   1.00  
  1 or more 605 (26.8) 1,580 (23.5) 1.23 (1.09, 1.38) 0.001 1.14 (0.99, 1.31) 0.07 1.19 (0.93, 1.52) 0.17
No. prescriptions low dose       
  0 1,653 (73.2) 5,153 (76.5) 1.00   1.00   1.00  
  1 to 11 246 (10.9) 704 (10.5) 1.11 (0.95, 1.31) 0.19 1.04 (0.87, 1.25) 0.64 1.13 (0.83, 1.56) 0.42
  12 or more 359 (15.9) 876 (13.0) 1.33 (1.15, 1.54) <0.001 1.24 (1.04, 1.47) 0.02 1.23 (0.92, 1.66) 0.17
No. tablets low dose       
  0 1,653 (73.2) 5,153 (76.5) 1.00   1.00   1.00  
  1 to 365 192 (8.5) 487 (7.2) 1.25 (1.05, 1.50) 0.01 1.21 (0.99, 1.47) 0.06 1.18 (0.84, 1.67) 0.33
  366 or more 413 (18.3) 1,093 (16.2) 1.21 (1.06, 1.39) 0.006 1.10 (0.94, 1.30) 0.23 1.19 (0.90, 1.59) 0.22
No. tablets (low dose) per day         
  0 1,653 (73.2) 5,153 (76.5) 1.00   1.00   1.00  
  0 to 0.5 225 (10.0) 590 (8.8) 1.21 (1.02, 1.44) 0.03 1.15 (0.95, 1.38) 0.16 1.22 (0.88, 1.67) 0.23
  >0.5 380 (16.8) 990 (14.7) 1.24 (1.07, 1.42) 0.003 1.14 (0.97, 1.34) 0.12 1.17 (0.87, 1.57) 0.30
No prescriptions high dose         
  0 2,222 (98.4) 6,660 (98.9) 1.00   1.00   1.00  
  1 or more 36 (1.6) 69 (1.0) 1.48 (0.99, 2.21) 0.05 1.24 (0.81, 1.89) 0.32 0.94 (0.48, 1.84) 0.86
  1. aModel includes chemotherapy within six months of diagnosis, radiotherapy within six months, tamoxifen (post diagnosis, during exposure period), aromatase inhibitors (post diagnosis, during exposure period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral vascular disease, peptic ulcer disease and diabetes), other medication exposure (post diagnosis, during exposure period, including statins, beta-blockers, ACE inhibitors, ARBs and metfomin), and smoking (pre-diagnosis, with missing included as a category).
  2. bAdjusted model additionally includes stage and grade, restricted to 888 cases and 2,628 controls with available data.
  3. CI, Confidence interval; OR, Odds ratio.